DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20163840

Analysis of invasive cervical cancer cases in Latvia

Anna Kornete, Elizabete Pumpure, Ronalds Macuks

Abstract


Background: The aim of the study is to evaluate the cervical cancer screening programme in Latvia and to determine how early cervical cancer diagnostics can be improved and the burden of the disease can be reduced.

Methods: All cervical cancer cases diagnosed in 2014 and treated in Oncology Centre of Latvia were included in the retrospective cross-sectional study. Cervical cancer cases were classified according to the cytological sampling interval: a “short” (<3 years), a “regular” (3–5 years) or a “long” (>5 years) interval.

Results: There were 189 patients identified during the study period. Information was obtained from 130 (68.7%) patients. 49.2% (n=64) of all patients had had a cytological examination within the last three years. For 11.6% (n=15) women, the screening interval was regular, while 21.5% (n=28) had had their last cytological examination more than five years before. 17.7% (n=23) had never had cytological examination. A tendency for more frequent early stage cervical cancer detection in the group of cytological sampling interval less than three years compared to a 3–5 years interval (71.9% vs. 53.3%, p=0.003) was observed.

Conclusions: In Latvia, cervical cancer is an unresolved healthcare issue for women. Despite the fact that lack of a quality management system, diagnostic imperfections and non-attendance in the organized, cytology-based screening programme remain the main barrier of cervical cancer control, introduction of a more sensitive test, such as primary testing for oncogenic human papilloma virus types, could significantly reduce the burden of the disease.


Keywords


Invasive cervical cancer, Screening programme, Cytology, Human papilloma virus

Full Text:

PDF

References


American Cancer Society. Global Cancer Facts and Figures 3rd Edition, 2015. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-044738.pdf. Accessed 12 December 2015.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-86.

The Centre for Disease Prevention and Control. Statistical Yearbook of Health Care in Latvia 16th edition, 2015. Available at file:///C:/Mani%20Dokumenti/Lejupielades/0_Ievads_saturs_2014.pdf. Accessed 4 November 2015.

The World Bank. World Development Indicators 2014. Available at http://wdi.worldbank.org/tables. Accessed at 6 December 2015.

Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ. The Screening Histories of Women with Invasive Cervical Cancer, Connecticut. Am J Public Health. 1995;85:791-94.

Viberga I, Engele L, Baili P. Past, present and future of the cervical cancer screening in Latvia. Tumori. 2010;96:529-37.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-97.

Von Karsa L, Arbyn A, De Vuyst H, Dillner J, Dillner L, Franceschi S. Executive summary. In: European guidelines for quality assurance in cervical cancer screening. Second edition, Supplements. Anttila A, Arbyn A, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al (eds.). Office for Official Publications of the European Union, Luxembourg, 23-174.

Cuzick J, Clavel C, Petry K. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-01.

Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M. Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2013;17:1-27.

Moss S, Gray A, Legood R, Vessey M, Patnick J, Kitchener H. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ. 2006;332:83-5.

The National Health Service. Vēža savlaicīgas atklāšanas programmas rezultāti 2015. Available at http://www.vmnvd.gov.lv/lv/469-veselibas-aprupes-pakalpojumi/veza-savlaicigas-atklasanas-programma/626-veza-savlaicigas-atklasanas-programmas-rezultati. Accessed 1 February 2016.

TOMBOLA Group. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicenter randomized controlled trial. BMJ. 2009;339:2546-57.

Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;6:49-55.

Tidy J, Luesley D, Bowring J. NHS Cervical Screening Programme Colposcopy and Programme Management. PHE publications. 2016;20:1-108.

Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138:2745-51.

Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet. 2006;7:547-55.

Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89:88-93.

Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138:2428-38.